loading
Precedente Chiudi:
$8.91
Aprire:
$8.69
Volume 24 ore:
1.12M
Relative Volume:
1.11
Capitalizzazione di mercato:
$801.30M
Reddito:
-
Utile/perdita netta:
$-43.16M
Rapporto P/E:
-15.11
EPS:
-0.55
Flusso di cassa netto:
$-29.31M
1 W Prestazione:
-14.54%
1M Prestazione:
+0.49%
6M Prestazione:
+5.65%
1 anno Prestazione:
+114.32%
Intervallo 1D:
Value
$8.20
$8.7899
Intervallo di 1 settimana:
Value
$8.20
$9.6914
Portata 52W:
Value
$3.51
$14.44

Anavex Life Sciences Corporation Stock (AVXL) Company Profile

Name
Nome
Anavex Life Sciences Corporation
Name
Telefono
844-689-3939
Name
Indirizzo
630 5TH AVENUE, NEW YORK
Name
Dipendente
2
Name
Cinguettio
@anavexlifesci
Name
Prossima data di guadagno
2024-12-31
Name
Ultimi documenti SEC
Name
AVXL's Discussions on Twitter

Confronta AVXL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
AVXL
Anavex Life Sciences Corporation
8.23 801.30M 0 -43.16M -29.31M -0.55
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-12-06 Downgrade Cantor Fitzgerald Overweight → Neutral
2022-06-23 Iniziato Berenberg Buy
2021-09-23 Iniziato BTIG Research Buy
2020-12-16 Reiterato H.C. Wainwright Buy
2020-09-28 Iniziato Ladenburg Thalmann Buy
2020-02-27 Iniziato Cantor Fitzgerald Overweight
2019-06-18 Iniziato Janney Buy
2018-05-16 Ripresa Maxim Group Buy
2018-03-08 Iniziato ROTH Capital Buy
2018-02-13 Reiterato Maxim Group Buy
2017-09-29 Ripresa Noble Financial Buy
2017-02-07 Iniziato Noble Financial Buy
2016-03-29 Iniziato FBR Capital Outperform
Mostra tutto

Anavex Life Sciences Corporation Borsa (AVXL) Ultime notizie

pulisher
May 06, 2025

Closing Bell Recap: Anavex Life Sciences Corporation (AVXL) Ends at 8.91, Reflecting a -4.81 Downturn - DWinneX

May 06, 2025
pulisher
May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Fina - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Anavex Life Sciences Earnings Preview: Key Updates Coming on Alzheimer's and Rare Disease Programs - Stock Titan

May 06, 2025
pulisher
May 04, 2025

Envestnet Asset Management Inc. Purchases 20,771 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

May 04, 2025
pulisher
May 04, 2025

Head-To-Head Comparison: Anavex Life Sciences (NASDAQ:AVXL) vs. Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World

May 04, 2025
pulisher
May 02, 2025

Taking on analysts’ expectations and winning: Anavex Life Sciences Corporation (AVXL) - Sete News

May 02, 2025
pulisher
May 02, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by JPMorgan Chase & Co. - Defense World

May 02, 2025
pulisher
May 01, 2025

Anavex Life Sciences' Schizophrenia Clinical Study Completes Enrollment - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Anavex Life Sciences Corporation (AVXL) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia - The Manila Times

May 01, 2025
pulisher
May 01, 2025

Anavex Life Sciences Corporation [AVXL] Records 50-Day SMA of $8.86 - knoxdaily.com

May 01, 2025
pulisher
Apr 30, 2025

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference | AVXL Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Anavex Showcases Breakthrough CNS Drug Portfolio: CEO Details Multiple Disease Targets at Citizens Conference - Stock Titan

Apr 30, 2025
pulisher
Apr 30, 2025

Wells Fargo & Company MN Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 30, 2025
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 24, 2025

Anavex Life Sciences Corporation’s Market Journey: Closing Strong at 9.31, Up 1.09 - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Buying Buzz: Anavex Life Sciences Corporation [AVXL] Director Donhauser Peter D.O. purchases 2,835 shares of the company – Knox Daily - knoxdaily.com

Apr 24, 2025
pulisher
Apr 23, 2025

AVXL overperforms with a 5.14 increase in share price - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Harvard-Trained Alzheimer's Pioneer With 35,000-Patient Database Strengthens Anavex's Scientific Team - Stock Titan

Apr 23, 2025
pulisher
Apr 23, 2025

Anavex Life Sciences Appoints Dr. Audrey Gabelle, MD, PhD To Scientific Advisory Board - citybiz

Apr 23, 2025
pulisher
Apr 21, 2025

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... - Yahoo Finance

Apr 21, 2025
pulisher
Apr 21, 2025

Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer’s Data ... By GuruFocus - Investing.com Canada

Apr 21, 2025
pulisher
Apr 21, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by LPL Financial LLC - Defense World

Apr 21, 2025
pulisher
Apr 21, 2025

Anavex Life Sciences Presents Novel Alzheimer Treatment Research at International Conference in Abu Dhabi - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East - TradingView

Apr 21, 2025
pulisher
Apr 20, 2025

Geode Capital Management LLC Has $20.14 Million Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 20, 2025
pulisher
Apr 19, 2025

Anavex Life Sciences Corp. (NASDAQ:AVXL) Holdings Raised by Alliancebernstein L.P. - Defense World

Apr 19, 2025
pulisher
Apr 13, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences LawsuitAVXL - ACCESS Newswire

Apr 13, 2025
pulisher
Apr 13, 2025

Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN

Apr 13, 2025
pulisher
Apr 13, 2025

Wellington Management Group LLP Makes New $1.70 Million Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 13, 2025
pulisher
Apr 13, 2025

Raymond James Financial Inc. Acquires Shares of 15,584 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Vanguard Group Inc. Sells 59,727 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 12, 2025
pulisher
Apr 10, 2025

Corebridge Financial Inc. Trims Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 10, 2025
pulisher
Apr 09, 2025

Four-Year Data on New Drug for Early AD Positive - streetwisereports.com

Apr 09, 2025
pulisher
Apr 08, 2025

Biotech Company Finds High-Impact Alzheimer's Therapy in Europe - streetwisereports.com

Apr 08, 2025
pulisher
Apr 08, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given Buy Rating at HC Wainwright - Defense World

Apr 08, 2025
pulisher
Apr 08, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years - Benzinga

Apr 07, 2025
pulisher
Apr 05, 2025

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease - The Manila Times

Apr 05, 2025
pulisher
Apr 05, 2025

Breakthrough: New Alzheimer's Drug Cuts Cognitive Decline Over 4 Years in Clinical Trial - Stock Titan

Apr 05, 2025
pulisher
Apr 05, 2025

Class Action Filed Against Anavex Life Sciences Corporation (AVXL) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Apr 05, 2025
pulisher
Apr 02, 2025

Class Action Filed Against Anavex Life Sciences Corporation (AVXL)May 13, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact Levi & Korsinsky about pending Class ActionAVXL - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

AVXL’s price-to-free cash flow ratio: What it means for investors - uspostnews.com

Apr 01, 2025
pulisher
Apr 01, 2025

Commonwealth Equity Services LLC Buys 7,285 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World

Apr 01, 2025
pulisher
Apr 01, 2025

Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Anavex Showcases Breakthrough CNS Therapies: CEO Details Pipeline at Major Healthcare Conference - Stock Titan

Mar 31, 2025

Anavex Life Sciences Corporation Azioni (AVXL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
Capitalizzazione:     |  Volume (24 ore):